<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573518</url>
  </required_header>
  <id_info>
    <org_study_id>BTX.2018.001</org_study_id>
    <nct_id>NCT03573518</nct_id>
  </id_info>
  <brief_title>Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Botanix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Botanix Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess safety and efficacy of various doses of BTX 1503&#xD;
      liquid formulation in subjects with moderate to severe acne vulgaris of the face.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, double-blinded, vehicle-controlled, parallel group,&#xD;
      dose-finding study in pediatrics, adolescents and adults (aged 12 to 40 years). The objective&#xD;
      of this study is to assess the safety and efficacy of various doses of BTX 1503 in subjects&#xD;
      with moderate to severe acne vulgaris of the face.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Actual">September 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change from Baseline in inflammatory lesion counts</measure>
    <time_frame>Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from Baseline in non-inflammatory lesion counts</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline in inflammatory lesion counts</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline in non-inflammatory lesion counts</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least a 2-grade reduction from Baseline IGA</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an IGA score of &quot;clear&quot; or &quot;almost clear&quot;</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an IGA score of &quot;clear&quot; or &quot;almost clear&quot; and at least 2-grade reduction from Baseline IGA</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>BTX 1503 Dose 1 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTX 1503 Dose 1 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTX 1503 Dose 1 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTX 1503 Dose 1 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTX 1503 Dose 2 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTX 1502 Dose 2 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTX 1503</intervention_name>
    <description>BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation</description>
    <arm_group_label>BTX 1503 Dose 1 BID</arm_group_label>
    <arm_group_label>BTX 1503 Dose 1 QD</arm_group_label>
    <arm_group_label>BTX 1503 Dose 2 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Vehicle BID</arm_group_label>
    <arm_group_label>Vehicle QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject (or legal guardian) has the ability and willingness to sign a written informed&#xD;
             consent/assent.&#xD;
&#xD;
          2. Subject is of either gender and 12 to 40 years of age.&#xD;
&#xD;
          3. Subject is in good general health without clinically significant haematological,&#xD;
             cardiac, respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or&#xD;
             malignant disease, as determined by the investigator.&#xD;
&#xD;
          4. Subject has suitable venous access for blood sampling.&#xD;
&#xD;
          5. Subject is able and willing to complete the study and to comply with all study&#xD;
             instructions and attend the necessary visits.&#xD;
&#xD;
          6. Subject has acne vulgaris of the face defined as:&#xD;
&#xD;
               1. 20 to 50 (inclusive) inflammatory lesions on the face&#xD;
&#xD;
               2. 20 to 100 (inclusive) non-inflammatory lesions on the face&#xD;
&#xD;
               3. An Investigator's Global Assessment (IGA) score for acne severity of 3 or 4&#xD;
                  (moderate or severe) assessed on the face.&#xD;
&#xD;
          7. Subject has ≤ 2 nodular/cystic acne lesions (&gt;5 mm in diameter).&#xD;
&#xD;
          8. Subject must refrain from the use of other treatments for acne during the study.&#xD;
&#xD;
          9. Subject must agree to not wash or shave their face, swim or otherwise get their face&#xD;
             wet for at least 1 hour after application of study medication.&#xD;
&#xD;
         10. Subject must agree to maintain their regular use of sunscreens, moisturizers, shaving&#xD;
             cream, and facial make up throughout the entire course of the study.&#xD;
&#xD;
         11. Male subjects and their partners must agree and commit to use a barrier method of&#xD;
             contraception during the study and for 90 days after last study drug application.&#xD;
&#xD;
         12. A negative UPT result for all WOCBP at the Screening Visit and Baseline Visit, if&#xD;
             applicable. A WOCBP is one who is not permanently sterilized or is not postmenopausal.&#xD;
             Postmenopausal is defined as 24 months with no menses without an alternative medical&#xD;
             cause.&#xD;
&#xD;
         13. Sexually active women must agree to use the following throughout the study and for 30&#xD;
             days after last study drug application:&#xD;
&#xD;
             a. One of these highly effective contraception methods i. Intrauterine device (IUD);&#xD;
             hormonal (injections, implants, transdermal patch, vaginal ring; tubal ligation;&#xD;
             partner vasectomy, OR b. Oral contraceptives WITH a barrier method (listed below), OR&#xD;
             c. Two barrier forms of contraception (listed below) i. Male or female condom;&#xD;
             diaphragm; cervical cap.&#xD;
&#xD;
         14. Male subjects must refrain from sperm donation during the study treatment period until&#xD;
             90 days after final study drug administration.&#xD;
&#xD;
         15. Male subjects must agree to keep their face clean shaven (no moustache or goatee;&#xD;
             short sideburns acceptable) throughout the study and use the same method for shaving&#xD;
             as was used for the 4 weeks prior to the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. People who would otherwise qualify for the study but are living in the same household&#xD;
             as a study subject, are not allowed to participate in the study.&#xD;
&#xD;
          2. Female subject who is breast feeding, pregnant, or planning to become pregnant any&#xD;
             time during the course of the study.&#xD;
&#xD;
          3. Subject with history of known or suspected intolerance to the drug product excipients.&#xD;
&#xD;
          4. Subject has known HIV infection.&#xD;
&#xD;
          5. Subject has acne conglobata, acne fulminans, secondary acne (chloracne),&#xD;
             pseudo-folliculitis, severe acne requiring systemic treatment, or is taking a&#xD;
             medication known to induce or exacerbate acne.&#xD;
&#xD;
          6. Subject has severe truncal acne.&#xD;
&#xD;
          7. Subject has excessive facial hair that would interfere with the evaluation of safety&#xD;
             or with the diagnosis or assessment of acne vulgaris.&#xD;
&#xD;
          8. Subject has sunburns, unevenness in skin tones, tattoos, scars, excessive hair,&#xD;
             freckles, birthmarks, moles, or other skin damage or abnormality that would result in&#xD;
             the inability to evaluate the skin of the face.&#xD;
&#xD;
          9. Subject has any skin condition of the face other than acne vulgaris.&#xD;
&#xD;
         10. Subject has used oral retinoid (e.g. isotretinoin) within 6 months (180 days) prior to&#xD;
             the Baseline Visit.&#xD;
&#xD;
         11. Subject has used Vitamin A supplements greater than 10,000 units/day within 6 months&#xD;
             (180 days) prior to the Baseline Visit.&#xD;
&#xD;
         12. Subject has used androgen receptor blockers (such as spironolactone or flutamide)&#xD;
             within 3 months (90 days) prior to the Baseline Visit.&#xD;
&#xD;
         13. Subject has initiated treatment with hormonal therapy or changed dosing with hormonal&#xD;
             therapy within 3 months (90 days) prior to the Baseline Visit.&#xD;
&#xD;
         14. Subject has had facial procedures (chemical or laser peel, microdermabrasion, etc.)&#xD;
             within 8 weeks (56 days) prior to the Baseline Visit.&#xD;
&#xD;
         15. Subject has had treatment with systemic antibiotics within 4 weeks (28 days) prior to&#xD;
             the Baseline Visit.&#xD;
&#xD;
         16. Subject has had treatment with systemic anti-acne drugs within 4 weeks (28 days) prior&#xD;
             to the Baseline Visit.&#xD;
&#xD;
         17. Subject has had treatment with systemic anti-inflammatory drugs within 4 weeks (28&#xD;
             days) prior to the Baseline Visit.&#xD;
&#xD;
         18. Subject has had treatment with systemic (oral) corticosteroids other immunosuppressive&#xD;
             medications within 4 weeks (28 days) prior to the Baseline Visit.&#xD;
&#xD;
         19. Subject has had treatment with prescription topical retinoid use on the face (e.g.&#xD;
             tretinoin, tazarotene) within 4 weeks (28 days) prior to the Baseline Visit.&#xD;
&#xD;
         20. Subject has had treatment with topical prescription antibiotics (e.g. dapsone,&#xD;
             clindamycin, erythromycin, or sulfacetamide) or combination products that include a&#xD;
             topical antibiotic within 2 weeks (14 days) prior to the Baseline Visit.&#xD;
&#xD;
         21. Subject has had treatment with over-the-counter (OTC) topical medications for the&#xD;
             treatment of acne vulgaris including benzoyl peroxide, topical anti- inflammatory&#xD;
             medications, corticosteroids, adapalene, α-hydroxy/glycolic acid on the face within 2&#xD;
             weeks (14 days) prior to the Baseline Visit.&#xD;
&#xD;
         22. Subject is currently using any medication that, in the opinion of the investigator,&#xD;
             may affect the evaluation of the study product or place the subject at undue risk.&#xD;
&#xD;
         23. Subject has had photodynamic therapy within 8 weeks (56 days) prior to the Baseline&#xD;
             Visit.&#xD;
&#xD;
         24. Subject has used a tanning bed within 2 weeks (14 days) prior to the Baseline Visit.&#xD;
&#xD;
         25. Subject has used home-based light treatment within 2 weeks (14 days) prior to the&#xD;
             Baseline Visit.&#xD;
&#xD;
         26. Subject has an underlying disease that requires the use of interfering topical or&#xD;
             systemic therapy.&#xD;
&#xD;
         27. Subject has other dermatological conditions that require the use of interfering&#xD;
             topical or systemic therapy or that might interfere with study assessments such as,&#xD;
             but not limited to, atopic dermatitis, psoriasis, perioral dermatitis, or rosacea.&#xD;
&#xD;
         28. Subject has had excessive sun exposure (in the opinion of the investigator) within one&#xD;
             week prior to the Baseline Visit and an unwillingness to refrain from excessive sun&#xD;
             exposure during the study.&#xD;
&#xD;
         29. Subject has a clinically relevant history or currently suffering from any disease or&#xD;
             condition that, in the opinion of the investigator, may affect the evaluation of the&#xD;
             study product or place the subject at undue risk. This may include respiratory&#xD;
             (including chronic asthma requiring repetitive drug interventions), gastrointestinal,&#xD;
             renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric,&#xD;
             musculoskeletal, genitourinary, immunological, dermatological, or connective tissue&#xD;
             diseases or disorders.&#xD;
&#xD;
         30. Subject has a clinically relevant history of, or current evidence of, abuse of alcohol&#xD;
             or other drugs. Subjects may be deemed eligible if the UDS identifies&#xD;
             subject-reported, prescribed drugs or appropriate levels of alcohol, as determined by&#xD;
             the investigator.&#xD;
&#xD;
         31. Subject has participated in another investigational drug or device research study&#xD;
             within 4 weeks (28 days) of the Baseline Visit or five half-lives of the drug,&#xD;
             whichever is longer.&#xD;
&#xD;
         32. Any other reason that would make the subject, in the opinion of the investigator or&#xD;
             sponsor, unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encino Research Center</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialist, Inc.</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Dermatology Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Insitute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Phrama Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tory Sullivan, M.D., PA</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research - Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delricht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Boston Clinical</name>
      <address>
        <city>Brighton</city>
        <state>Maine</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisearch Clinical Trials</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JDR Dermatology Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Acne Treatment and Research Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Dermatology, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermReasearch</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cmax Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burswood Dermatology</name>
      <address>
        <city>Burwood</city>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin &amp; Canver Foundation Inc.</name>
      <address>
        <city>Carlton</city>
        <zip>053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Dermatology</name>
      <address>
        <city>Fremantle</city>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Eastern Health Specialist</name>
      <address>
        <city>Hectorville</city>
        <zip>5073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Dermatology &amp; Skim Cancer Center</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Captain Sterline Medical Centre</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woden Dermatology</name>
      <address>
        <city>Phillip</city>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Varacity Clinical Research</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Synthetic CBD</keyword>
  <keyword>Cannabidiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

